ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,487.03
      0.25%
      US Tech 100
      19,430.40
      0.14%
      Dow Jones
      38,834.86
      0.15%
      Brent Oil
      84.885
      0.12%
      Bitcoin
      65,159.19
      0.03%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Incyte Corporation (INCY)

      7. Incyte Corporation (INCY) News

      INCY

      Incyte (INCY)

      Incyte Corporation
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INCY
      DateTimeSourceHeadlineSymbolCompany
      03/24/20237:25AMBusiness WireIncyte fournit une mise à jour réglementaire sur les comprimés de ruxolitinib à libération prolongéeNASDAQ:INCYIncyte Corporation
      03/24/20237:22AMBusiness WireIncyte legt Aktualisierung zum regulatorischen Stand von Ruxolitinib-Tabletten mit Langzeitwirkung vorNASDAQ:INCYIncyte Corporation
      03/24/20236:39AMDow Jones NewsFDA Rejects Incyte's Bid for Once-Daily Jakafi ApprovalNASDAQ:INCYIncyte Corporation
      03/24/202312:23AMBusiness WireIncyte meldet FDA-Zulassung für Zynyz™ (Retifanlimab-dlwr) für die Behandlung von metastasierendem oder rezidivierendem, lokal fortgeschrittenem Merkelzellkarzinom (MCC)NASDAQ:INCYIncyte Corporation
      03/23/20238:55PMBusiness WireIncyte Provides Regulatory Update on Ruxolitinib Extended-Release TabletsNASDAQ:INCYIncyte Corporation
      03/23/20231:48AMBusiness WireIncyte annonce l'approbation de la FDA pour Zynyz™ (retifanlimab-dlwr) dans le traitement du carcinome à cellules de Merkel (CCM) métastatique ou récurrent localement avancéNASDAQ:INCYIncyte Corporation
      03/22/20232:19PMDow Jones NewsIncyte Gets FDA Approval of Zynyz, Triggers Milestone Payment to MacroGenicsNASDAQ:INCYIncyte Corporation
      03/22/20231:14PMBusiness WireIncyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)NASDAQ:INCYIncyte Corporation
      03/18/20233:40PMBusiness WireIncyte Announces Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoNASDAQ:INCYIncyte Corporation
      03/18/202310:40AMBusiness WireIncyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of Opzelura® (Ruxolitinib) Cream in VitiligoNASDAQ:INCYIncyte Corporation
      03/15/20234:11PMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:INCYIncyte Corporation
      03/15/20234:04PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      03/14/20236:30PMBusiness WireIncyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023NASDAQ:INCYIncyte Corporation
      03/07/20236:30AMPR Newswire (US)Caris Life Sciences and Incyte Enter Into Broad Precision Medicine Partnership to Advance Incyte's Oncology PipelineNASDAQ:INCYIncyte Corporation
      03/07/20233:05AMBusiness WireMehrere Abstracts aus dem wachsenden Dermatologie-Portfolio von Incyte werden beim Jahrestreffen der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
      03/06/20239:46PMBusiness WirePlusieurs résumés de la gamme grandissante de produits dermatologiques d'Incyte présentés lors du congrès annuel de l'American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
      03/06/202312:23PMBusiness WireMultiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
      03/03/20234:35PMBusiness WireIncyte Provides Update on Interim Analysis of Phase 3 LIMBER-304 Study of Parsaclisib and Ruxolitinib in Patients with MyelofibrosisNASDAQ:INCYIncyte Corporation
      02/24/20238:01PMBusiness WireIncyte meldet positive CHMP-Stellungnahme für Ruxolitinib-Creme (Opzelura™) zur Behandlung von nicht segmentaler Vitiligo bei Erwachsenen und JugendlichenNASDAQ:INCYIncyte Corporation
      02/24/20232:48PMBusiness WireIncyte annonce l'avis favorable du CHMP pour la crème Opzelura™ (ruxolitinib) pour le traitement du vitiligo non segmentaire chez les malades adultes et adolescentsNASDAQ:INCYIncyte Corporation
      02/24/20237:07AMBusiness WireIncyte Announces Positive CHMP Opinion for Ruxolitinib Cream (Opzelura™) for the Treatment of Non-segmental Vitiligo in Adults and AdolescentsNASDAQ:INCYIncyte Corporation
      02/21/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      02/16/20238:00AMBusiness WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
      02/15/20234:01PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:INCYIncyte Corporation
      02/11/20235:36AMBusiness WireIncyte gibt 52-Wochen-Ergebnisse der Phase-II-Studie mit Povorcitinib (INCB54707) bei Patienten mit Hidradenitis suppurativa bekanntNASDAQ:INCYIncyte Corporation
      02/10/20232:58PMBusiness WireIncyte annonce les résultats à 52 semaines de l’étude de Phase 2 évaluant le povorcitinib (INCB54707) chez les patients atteints d'hidradénite suppuréeNASDAQ:INCYIncyte Corporation
      02/10/20238:20AMBusiness WireIncyte Announces 52-Week Results from Phase 2 Study Evaluating Povorcitinib (INCB54707) in Patients with Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
      02/09/202311:33AMEdgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:INCYIncyte Corporation
      02/07/20234:03PMEdgar (US Regulatory)Annual Report (10-k)NASDAQ:INCYIncyte Corporation
      02/07/20237:06AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:INCYIncyte Corporation
       Showing the most relevant articles for your search:NASDAQ:INCY